Evolus Q3 revenue rises, reaffirms 2025 revenue forecast

Evolus

05/11/2025 22:04

Overview

Evolus Q3 2025 revenue rises 13% yr/yr, driven by Jeuveau and Evolysse growth

Company expects positive non-GAAP operating income in Q4 2025

Evolus reaffirms 2025 revenue guidance of $295 mln to $305 mln

Outlook

Evolus reaffirms 2025 net revenue guidance of $295 mln to $305 mln

Company expects positive non-GAAP operating income of $5 mln to $7 mln in Q4 2025

Evolus plans U.S. launch of Evolysse™ Sculpt in 2026 and Evolysse™ Lips in 2027

Result Drivers

JEUVEAU GROWTH - Sequential growth in Jeuveau revenue outperformed typical seasonal trends

EVOLYSSE LAUNCH - Evolysse delivered $5.7 mln in revenue, marking the strongest HA filler debut in over a decade

EXPENSE MANAGEMENT - Strategic mid-year expense reductions lowered operating costs, strengthening financial position

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Product Revenue
$68.97 mln
Q3 Net Income
-$15.74 mln
Q3 Gross Margin
66.50%
Q3 Adjusted Gross Margin
67.60%
Q3 Gross Profit
$45.84 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Evolus Inc is $19.50, about 67.1% above its November 4 closing price of $6.41

The stock recently traded at 33 times the next 12-month earnings vs. a P/E of 30 three months ago

Press Release: ID:nBw58Mr31a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)